Figure 1A




Figure 1B




Figure 2



Biotinylated IL-23 binding
to plate-immobilized anti-IL-23 mAbs
OD
2.0
1.5
1.0
0.5
0.0
10-3
10-2
10-1
100
101
102
103
bt.IL-23, ng/ml
MOR04190
MOR04083 (run separately)

Figure 3A



IL-23bt./IL-23R-Fc BRBA in the presence of MOR mAbs
0.75
0.50
0.25
0.00
OD
0.001
0.01
0.1
1
10
100
mAb, ug/ml
IL-23R-Fc
MOR04083
MOR04190
B21M
IL-23 no mAbs

Figure 3B



IL-23 binding to plate - Immobilized IL-12Rβ1-Fc
In the presence of mAbs
20 ng/ml bt.IL-23 used
OD
2
1
0
10-2
10-1
100
101
102
mAb, ug/ml
MOR04083
MOR04190
IL-23 no mAbs
CNTO1275
Neg.mAb

Fig. 3C



IL-12/IL-12Rb1-Fc binding
in the presence of anti-IL-23 mAbs
mAbs used at 30 ug/ml
OD
3
2
1
0
Neg.mAb
MOR04083
MOR04190
MOR04217
CNTO1275
No mAbs

Figure 4



Key
Name
no IL-23.002
IL-23.001
IL-23+mAb12A (1).00
IL-23+C8.3 (10).004
4083 @
4190 @
80
40
0
10^0
10^1

Figure 5A



IL-23-induced IL-17 production
in the presence of anti-IL-23 mAbs
IL-17, pg/ml
1200
950
700
450
200
10-4
10-3
10-2
10-1
100
101
102
mAb, ug/ml
CNTO1275
MOR04083
CNTO95
IL-23 alone
No IL-23
MOR04190

Figure 5B



Native IL-23 induced IL- 17 production
from murine splenocytes in the presence
or absence of anti-human IL-23 mAbs
Human PBMC CM (lot 1/99, 0.5%)
used as a source of hIL-23
IL-17, pg/ml
150
100
50
0
10-4
10-3
10-2
10-1
100
101
102
mAb, ug/ml
CNTO1275
Neg.mAb
MOR04190
MOR04083
No IL-23
IL-23 no mAbs

Figure 5C



Cyno PBMC CM - induced IL-17 production
from murine splenocytes
in the presence of anti-human IL-23 mAbs
IL-17, pg/ml
1200
950
700
450
200
0.001
0.01
0.1
1
10
100
mAbs, ug/ml
MOR04083
MOR04190
CNTO1275
B21M
CyCM no mAbs
no CM

Figure 6



IL-12 - Induced IFNg production from NK92MI cells
in the presence of anti-IL-23 mAbs
IFNγ, pg/ml
450
350
250
150
50
0.001
0.01
0.1
1
10
100
mAb, ug/ml
MOR04083
MOR04190
CNTO1275
IL-12 no mAbs
No IL-12

Figure 7A





Figure 7B






Figure 7C

Figure 8



IL-17 production assay in the presence of MOR mAbs
Murine splenocytes, Native human IL-23
IL-17, pg/ml
2000
1500
1000
500
0
10-4
10-3
10-2
10-1
100
101
102
mAb, ug/ml
5042
5045
5040
5038
5053
5049
5028
mAb23A
IL-23 no mAb

Figure 9




IL-23 binding to plate-immobilized IL-23R-Fc
in the presence of MOR mAbs
(20ng/ml IL-23-bt. used)
OD
0.6
0.5
0.4
0.3
0.2
0.1
0.0
10-4
10-3
10-2
10-1
100
101
102
mAb, ug/ml
anti-CD28
5042
5045
5040
5038
5053
5049
5028
mAb23A
IL-23
no mAb

Figure 10



IL23

Figure 11A



IL-23 binding to plate-immobilized IL-23R-Fc
in the presence of anti-IL-23p19 mAbs
(20ng/ml IL-23-bt. used)
OD
0.9
0.6
0.3
0.0
10⁻⁴
10⁻³
10⁻²
10⁻¹
10⁰
10¹
10²
mAb, ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
Neg. mAb
IL-23 alone

Figure 11B



IL-23 binding to plate-immobilized IL-12Rβ1-Fc
in the presence of anti-IL-23p19 mAbs
(20ng/ml IL-23-bt. used)
1.2
0.9
0.6
0.3
0.0
OD
10⁻⁴
10⁻³
10⁻²
10⁻¹
10⁰
10¹
10²
mAb, ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
Neg. mAb
IL-23 alone

Figure 11C



IL-12 binding to plate-immobilized IL-12Rβ1-Fc
in the presence of anti-IL-23p19 mAbs
(10ng/ml IL-12 used, binding detected w/anti-IL-12/23p40 (C330) -bt.)
OD
1.75
1.50
1.25
1.00
0.75
0.50
0.25
0.00
10⁻⁴
10⁻³
10⁻²
10⁻¹
10⁰
10¹
10²
mAb, ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
Neg. mAb
IL-12 alone

Figure 12



Native human IL-12 induced
IFNg production from NK92MI cells
In the presence of anti-IL-23p19 mAbs
IFNg, pg/ml
175
150
125
100
75
50
25
0
10-4
10-3
10-2
10-1
100
101
102
Ab ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
IL-12 no mAb
No IL-12

Figure 13



rhIL-23 induced IL-17 production
from murine splenocytes
in the presence of anti-IL-23p19 mAbs
IL-17, pg/ml
500
400
300
200
100
0
10-5
10-4
10-3
10-2
10-1
100
101
mAb ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
Neg. mAb
IL-23 no mAb
No IL-23

Figure 14



Native human IL-23 induced IL-17 production
from murine splenocytes
in the presence of anti-IL-23p19 mAbs
IL-17, pg/ml
1250
1000
750
500
250
0
10-5
10-4
10-3
10-2
10-1
100
101
mAb ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
Neg.mAb
IL-23 no mAb
No IL-23

Figure 15



Native cyno IL-23 induced IL-17 production
from murine splenocytes
in the presence of anti-IL-23p19 mAbs
IL-17, pg/ml
450
400
350
300
250
200
150
100
50
0
10-5
10-4
10-3
10-2
10-1
100
101
mAb ug/ml
mAb23A
5040Q/EV
3759EQ/QS
mAb12A
Neg. mAb
IL-23 no mA
No IL-23

Figure 16A



Anti-IL-23 mAb competition assay
mAb23A immobilized on a plate plate at 5 ug/ml,
bt.IL-23 used at 20 ng/ml
1.10
0.55
0.00
OD
10-4
10-3
10-2
10-1
100
101
102
Ab ug/ml
mAb23A
5040Q/EV
3759EQ/QS
B21M
IL-23 no mAb

Figure 16B




Anti-IL-23 mAb competition assay
5040Q/EV immobilized on a plate plate at 5 ug/ml,
bt.IL-23 used at 20 ng/ml
OD
2.0
1.5
1.0
0.5
0.0
10-4
10-3
10-2
10-1
100
101
102
Ab ug/ml
mAb23A
5040Q/EV
3759EQ/QS
B21M
IL-23 no mAb

Figure 16C


Anti-IL-23 mAb competition assay
3759EQ/QS immobilized on a plate plate at 5 ug/ml,
bt.IL-23 used at 20 ng/ml
1.4
0.7
0.0
OD
10-4
10-3
10-2
10-1
100
101
102
Ab ug/ml
mAb23A
5040Q/EV
3759EQ/QS
B21M
IL-23 no mAb